CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤治疗展望
英文原题：Perspectives on the Treatment of Multiple Myeloma.
查看英文原题
Perspectives on the Treatment of Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去几十年来，随着新型治疗方法的开发，多发性骨髓瘤的治疗已发生显著演变。蛋白酶体抑制剂、免疫调节药物、单克隆抗体以及大剂量化疗后行造血干细胞移植的引入，改善了缓解率和生存结局。双特异性抗体和CAR-T 细胞疗法的应用目前正在研究中，早期结果显示出良好前景。尽管随着新疗法的开发，MM患者的结局有所改善，但仍有一部分高危疾病患者预后特别差。因此，未来的临床试验必须重点关注专门针对高危多发性骨髓瘤开发新疗法。在此，我们回顾文献并为执业肿瘤科医生提供多发性骨髓瘤患者治疗的指导。
展开英文摘要原文
The treatment of multiple myeloma has evolved significantly over the past few decades with the development of novel therapeutics. The introduction of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and high-dose chemotherapy followed by hematopoietic stem cell transplantation has led to improved response rates and survival outcomes.
The use of bispecific antibodies and chimeric antigen receptor T-cell therapy is currently under study, and early results are showing promise. Although outcomes for patients with MM have improved with the development of new treatments, there remains a subset of patients with high-risk disease who have a particularly poor prognosis.
Therefore, it is critical that future clinical trials focus on developing new therapies specifically for high-risk multiple myeloma.
Here we review the literature and provide guidance on treating patients with multiple myeloma for practicing oncologists.
论文信息
- 作者
- Rafae A、van Rhee F、Al Hadidi S
- 第一作者单位
- Department of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.United States
- 通讯作者单位
- Myeloma Institute, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.United States
- 文献类型
- 综述
- 期刊
- The oncologist2024 Mar 4
- 原文标识
- PubMed 37995307 · DOI 10.1093/oncolo/oyad306
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →